NeoGenomics, Inc. (NASDAQ:NEO) is now being followed by Needham, as they initiated the stock at Buy on January 03. Analysts at First Analysis Sec, shed their negative views on October 24 by lifting it fromOutperform to Strong Buy. Analysts at Leerink Partners, made their first call about the stock on August 21, recommending it is Outperform.
NeoGenomics, Inc. (NEO) hit an intraday high Friday at $15.59. The shares finished at $15.36, after trading as low as $14.83 earlier in the session. It rose 0.52% in recent trade and currently has a stock-market value of $1.43B. Trading activity significantly improved as the volume at ready counter increased to 19,107,422 shares versus 2,421,555 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 3,990,300 shares. The stock is now 116.95% above against its bear-market low of $7.08 on February 06, 2018. It has retreated -23.96% since it’s 52-week high of $19.04 reached in November. Now the market price is up 81.13% on the year and up 21.81% YTD.
NEO’s 50 day simple moving average (SMA 50) price is $14.92 and its 200-day simple moving average (SMA 200) price is $13.2. The company’s stock currently has a total float of 85.91M shares. Its weekly volatility is hovering around 4.41% and felt 4.74% volatility in price over a month. On the upside, the share price will test short term resistance at around $15.69. On a downside, the stock is likely to find some support, which begins at $14.93. The failure to get near-term support could push it to $14.5.
Separately, it has been reported that multiple insider activity took place at NeoGenomics, Inc. (NEO). Director Johnson Kevin C acquired 26,000 shares for $103,866 in transaction occurred on 2018/12/21. After making this transaction, the Director owns a direct stake of 301,600 shares, worth $1,595,382, as per the last closing price. On 2018/12/14 General Electric Co, at NEO, dumped 10,835,145 shares at an average price of $12 per share. The selling total is valued at $.
Director, Tetrault Lynn A. had divested 13,000 shares for $38,234 through a trade on 2018/11/19. Following this activity, the insider holds 208,000 shares worth $587,274 as of recent close. Wall Street’s most bullish NeoGenomics, Inc. (NASDAQ:NEO) analysts are predicting the share price to blow past $22 per share during the next 12 months. The current median share price forecast by them is $20.5, suggesting that the stock could increase 33.46% in that time frame. The average price target of $19.88 calls for a nearly 29.43% increase in the stock price.
When looking at valuations, NeoGenomics, Inc. (NEO) has a pricey P/E of 301.18x as compared to industry average of 27x. Moreover, it trades for 66.78 times the next 12 months of expected earnings. Also, it is trading at rather expensive levels at just over 4.41x price/book and 5.33x price/sales. Compared to others, NeoGenomics, Inc. is in a different league with regards to profitability, having net margins of 3%. To put some perspective around this, the industry’s average net margin is 3.1%. NEO’s ROE is 3.9%, which is also considerably worse than the industry’s ROE of 10.5%. It’s also very liquid in the near term, with a current ratio of 4.1. The stock has a debt/capital of 0.36.
Shares of NeoGenomics, Inc. (NEO) have dropped -4.2% since the company’s Mar-19 earnings report. Over the past 12 fiscal quarters, NeoGenomics, Inc. (NASDAQ:NEO) has topped consensus earnings estimates in 7 quarters (58%), missed earnings in 2 quarters (16%), whereas at 3 occasion EPS met analyst expectations. NEO last reported earnings on October 30, 2018 when it released Sep-18 results that exceeded expectations. The company raked in $0.05 per share, -99.95% change on the same period last year. That was better than consensus for $0.02. Revenue for the recent quarter stood at $69.1 million, up 10% on last year and above the $66.32 million predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $70.6 million to $94.44 million, which should be compared with $73.25 million generated last year. EPS is seen in a range of $0.05 to $0.06, against the $0.06 reported a year ago.